StockData
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. (MEDP) stock

MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 22, 2026Score 14/3042% above fair value
$646.87−6.22 (-0.95%)

Close on Nov 18, 2026Market cap $18.09BP/E 35.9Yield –

Medpace operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Medpace's operating income for the twelve months ending Sep 30, 2026 was $607.14M, up 19.7% year over year. For fiscal 2025 it was $534.94M, up 19.7% from the year before. Over ten years it grew 38.5% a year on average. The highest annual figure on record is $534.94M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$534.94M+19.7%
FY2024Dec 31, 2024$446.87M+32.7%
FY2023Dec 31, 2023$336.83M+20.9%
FY2022Dec 31, 2022$278.70M+40.3%
FY2021Dec 31, 2021$198.62M+18.9%
FY2020Dec 31, 2020$167.04M+31.3%
FY2019Dec 31, 2019$127.26M+25.9%
FY2018Dec 31, 2018$101.05M+55.8%
FY2017Dec 31, 2017$64.86M+23.6%
FY2016Dec 31, 2016$52.49M+155.3%
FY2015Dec 31, 2015$20.56M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$165.54M+16.7%
Q2 FY2026Jun 30, 2026$146.82M+16.2%
Q1 FY2026Mar 31, 2026$141.50M+24.6%
Q4 FY2025Dec 31, 2025$153.27M+22.2%
Q3 FY2025Sep 30, 2025$141.81M+26.3%
Q2 FY2025Jun 30, 2025$126.34M+20.1%
Q1 FY2025Mar 31, 2025$113.52M+9.1%
Q4 FY2024Dec 31, 2024$125.38M+43.6%
Q3 FY2024Sep 30, 2024$112.27M+32.2%
Q2 FY2024Jun 30, 2024$105.15M+34.1%
Q1 FY2024Mar 31, 2024$104.07M+20.7%
Q4 FY2023Dec 31, 2023$87.32M+14.2%
Q3 FY2023Sep 30, 2023$84.91M+9.1%
Q2 FY2023Jun 30, 2023$78.39M+30.1%
Q1 FY2023Mar 31, 2023$86.20M+34.3%
Q4 FY2022Dec 31, 2022$76.43M+39.3%
Q3 FY2022Sep 30, 2022$77.83M+44.9%
Q2 FY2022Jun 30, 2022$60.24M+41.9%
Q1 FY2022Mar 31, 2022$64.20M+34.9%
Q4 FY2021Dec 31, 2021$54.86M-0.2%
Q3 FY2021Sep 30, 2021$53.71M+15.7%
Q2 FY2021Jun 30, 2021$42.45M+40.9%
Q1 FY2021Mar 31, 2021$47.60M+34.1%
Q4 FY2020Dec 31, 2020$54.99M+52.2%
Q3 FY2020Sep 30, 2020$46.42M+54.8%
Q2 FY2020Jun 30, 2020$30.13M-14.6%
Q1 FY2020Mar 31, 2020$35.50M+37.1%
Q4 FY2019Dec 31, 2019$36.12M+17.8%
Q3 FY2019Sep 30, 2019$29.99M+11.4%
Q2 FY2019Jun 30, 2019$35.26M+51.0%
Q1 FY2019Mar 31, 2019$25.90M+28.7%
Q4 FY2018Dec 31, 2018$30.67M+98.7%
Q3 FY2018Sep 30, 2018$26.92M+56.5%
Q2 FY2018Jun 30, 2018$23.35M+43.4%
Q1 FY2018Mar 31, 2018$20.12M+26.2%
Q4 FY2017Dec 31, 2017$15.44M+19.8%
Q3 FY2017Sep 30, 2017$17.20M–
Q2 FY2017Jun 30, 2017$16.28M–
Q1 FY2017Mar 31, 2017$15.94M–
Q4 FY2016Dec 31, 2016$12.89M–

More Medpace figures

See a number that looks wrong?